Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. 2004

Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.

BACKGROUND We and others have reported that transient accumulation of cyclic AMP (cAMP) in the myocardium during ischemic preconditioning (IP) limits infarct size independent of protein kinase C (PKC). Accumulation of cAMP activates protein kinase A (PKA), which has been demonstrated to cause reversible inhibition of RhoA and Rho-kinase. We investigated the involvement of PKA and Rho-kinase in the infarct limitation by IP. RESULTS Dogs were subjected to 90-minute ischemia and 6-hour reperfusion. We examined the effect on Rho-kinase activity during sustained ischemia and infarct size of (1) preischemic transient coronary occlusion (IP), (2) preischemic activation of PKA/PKC, (3) inhibition of PKA/PKC during IP, and (4) inhibition of Rho-kinase or actin cytoskeletal deactivation during myocardial ischemia. Either IP or dibutyryl-cAMP treatment activated PKA, which was dose-dependently inhibited by 2 PKA inhibitors (H89 and Rp-cAMP). IP and preischemic PKA activation substantially reduced infarct size, which was blunted by preischemic PKA inhibition. IP and preischemic PKA activation, but not PKC activation, caused a substantial decrease of Rho-kinase activation during sustained ischemia. These changes were cancelled by preischemic inhibition of PKA but not PKC. Furthermore, either Rho-kinase inhibition (hydroxyfasudil or Y27632) or actin cytoskeletal deactivation (cytochalasin-D) during sustained ischemia achieved the same infarct limitation as preischemic PKA activation without affecting systemic hemodynamic parameters, the area at risk, or collateral blood flow. CONCLUSIONS Transient preischemic activation of PKA reduces infarct size through Rho-kinase inhibition and actin cytoskeletal deactivation during sustained ischemia, implicating a novel mechanism for cardioprotection by ischemic preconditioning independent of PKC and a potential new therapeutic target.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017346 Protein Serine-Threonine Kinases A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors. Protein-Serine-Threonine Kinases,Serine-Threonine Protein Kinase,Serine-Threonine Protein Kinases,Protein-Serine Kinase,Protein-Serine-Threonine Kinase,Protein-Threonine Kinase,Serine Kinase,Serine-Threonine Kinase,Serine-Threonine Kinases,Threonine Kinase,Kinase, Protein-Serine,Kinase, Protein-Serine-Threonine,Kinase, Protein-Threonine,Kinase, Serine-Threonine,Kinases, Protein Serine-Threonine,Kinases, Protein-Serine-Threonine,Kinases, Serine-Threonine,Protein Kinase, Serine-Threonine,Protein Kinases, Serine-Threonine,Protein Serine Kinase,Protein Serine Threonine Kinase,Protein Serine Threonine Kinases,Protein Threonine Kinase,Serine Threonine Kinase,Serine Threonine Kinases,Serine Threonine Protein Kinase,Serine Threonine Protein Kinases
D047908 Intracellular Signaling Peptides and Proteins Proteins and peptides that are involved in SIGNAL TRANSDUCTION within the cell. Included here are peptides and proteins that regulate the activity of TRANSCRIPTION FACTORS and cellular processes in response to signals from CELL SURFACE RECEPTORS. Intracellular signaling peptide and proteins may be part of an enzymatic signaling cascade or act through binding to and modifying the action of other signaling factors. Intracellular Signaling Peptides,Intracellular Signaling Proteins,Peptides, Intracellular Signaling,Proteins, Intracellular Signaling,Signaling Peptides, Intracellular,Signaling Proteins, Intracellular
D054460 rho-Associated Kinases A group of intracellular-signaling serine threonine kinases that bind to RHO GTP-BINDING PROTEINS. They were originally found to mediate the effects of rhoA GTP-BINDING PROTEIN on the formation of STRESS FIBERS and FOCAL ADHESIONS. Rho-associated kinases have specificity for a variety of substrates including MYOSIN-LIGHT-CHAIN PHOSPHATASE and LIM KINASES. rho-Associated Kinase,ROCK Protein Kinases,ROCK-I Protein Kinase,ROCK-II Protein Kinase,ROK Kinase,p160 rhoA-Binding Kinase ROKalpha,p160ROCK,rho-Associated Coiled-Coil Containing Protein Kinase 1,rho-Associated Coiled-Coil Containing Protein Kinase 2,rho-Associated Coiled-Coil Kinase,rho-Associated Kinase 1,rho-Associated Kinase 2,rho-Associated Kinase alpha,rho-Associated Kinase beta,rho-Associated Protein Kinase alpha,rho-Associated Protein Kinase beta,rho-Kinase,Coiled-Coil Kinase, rho-Associated,Protein Kinases, ROCK,ROCK I Protein Kinase,ROCK II Protein Kinase,p160 rhoA Binding Kinase ROKalpha,rho Associated Coiled Coil Containing Protein Kinase 1,rho Associated Coiled Coil Containing Protein Kinase 2,rho Associated Coiled Coil Kinase,rho Associated Kinase,rho Associated Kinase 1,rho Associated Kinase 2,rho Associated Kinase alpha,rho Associated Kinase beta,rho Associated Kinases,rho Associated Protein Kinase alpha,rho Associated Protein Kinase beta,rho Kinase
D017868 Cyclic AMP-Dependent Protein Kinases A group of enzymes that are dependent on CYCLIC AMP and catalyze the phosphorylation of SERINE or THREONINE residues on proteins. Included under this category are two cyclic-AMP-dependent protein kinase subtypes, each of which is defined by its subunit composition. Adenosine Cyclic Monophosphate-Dependent Protein Kinases,Protein Kinase A,cAMP Protein Kinase,cAMP-Dependent Protein Kinases,Cyclic AMP-Dependent Protein Kinase,cAMP-Dependent Protein Kinase,Adenosine Cyclic Monophosphate Dependent Protein Kinases,Cyclic AMP Dependent Protein Kinase,Cyclic AMP Dependent Protein Kinases,Protein Kinase, cAMP,Protein Kinase, cAMP-Dependent,Protein Kinases, cAMP-Dependent,cAMP Dependent Protein Kinase,cAMP Dependent Protein Kinases

Related Publications

Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
October 1998, Cardiovascular research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
June 1997, Circulation research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
October 2008, Experimental eye research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
April 2005, The Journal of surgical research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
September 1996, Annals of the New York Academy of Sciences,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
January 1999, Sheng li ke xue jin zhan [Progress in physiology],
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
August 2000, Circulation research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
May 2001, The Journal of surgical research,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
August 2011, Nitric oxide : biology and chemistry,
Shoji Sanada, and Hiroshi Asanuma, and Osamu Tsukamoto, and Tetsuo Minamino, and Koichi Node, and Seiji Takashima, and Tomi Fukushima, and Akiko Ogai, and Yoshiro Shinozaki, and Masashi Fujita, and Akio Hirata, and Hiroko Okuda, and Hiroaki Shimokawa, and Hitonobu Tomoike, and Masatsugu Hori, and Masafumi Kitakaze
August 2002, Cardiovascular research,
Copied contents to your clipboard!